Useful Oral Administration of Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) as Semaglutide (Rybelsus) for Type 2 Diabetes Mellitus (T2DM)
Open Access
- 22 February 2022
- journal article
- Published by Asploro Open Access Publications in Asploro Journal of Biomedical and Clinical Case Reports
- Vol. 5 (1), 38-41
- https://doi.org/10.36502/2022/asjbccr.6260
Abstract
As recommended pharmacological agents for type 2 diabetes mellitus (T2DM), Glucagon-Like Peptide 1 receptor agonist (GLP-1Ra) is highly evaluated for its various beneficial effects. Among them, semaglutide (Rybelsus) has been in focus for useful oral formation with useful oral hypoglycemic agent (OHA). Administration per os is possible due to the developed technique of absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate. Clinical efficacy was shown by a series of Peptide Innovation for Early Diabetes Treatment (PIONEER) with enough weight reduction and decreased HbA1c. From the results of several PIONEER programs, oral semaglutide 14 mg/day had reduced HbA1c values by approximately 1.0-1.4%.Keywords
This publication has 15 references indexed in Scilit:
- The cost–effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in DenmarkJournal of Comparative Effectiveness Research, 2022
- Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight ManagementJournal of Investigative Medicine, 2022
- A Review for Predicting the Diabetes Mellitus Using Different Techniques and MethodsPublished by Springer Science and Business Media LLC ,2021
- Author response for "Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials"Published by Wiley ,2021
- Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight lossDiabetes, Obesity and Metabolism, 2021
- Efficacy of Semaglutide in a Subcutaneous and an Oral FormulationFrontiers in Endocrinology, 2021
- Advances in oral peptide therapeuticsNature Reviews Drug Discovery, 2019
- Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trialThe Lancet, 2019
- Intestinal permeation enhancers for oral peptide deliveryAdvanced Drug Delivery Reviews, 2016
- Challenges in the delivery of peptide drugs: an industry perspectiveTherapeutic Delivery, 2015